MX391965B - Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. - Google Patents

Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.

Info

Publication number
MX391965B
MX391965B MX2018015916A MX2018015916A MX391965B MX 391965 B MX391965 B MX 391965B MX 2018015916 A MX2018015916 A MX 2018015916A MX 2018015916 A MX2018015916 A MX 2018015916A MX 391965 B MX391965 B MX 391965B
Authority
MX
Mexico
Prior art keywords
cancer
treatment
compositions useful
porphyrin compounds
porphyrin
Prior art date
Application number
MX2018015916A
Other languages
English (en)
Other versions
MX2018015916A (es
Inventor
Maria Zannes
Vivienne I Rebel
William E Bauta
Original Assignee
Oncoselect Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoselect Therapeutics Llc filed Critical Oncoselect Therapeutics Llc
Publication of MX2018015916A publication Critical patent/MX2018015916A/es
Publication of MX391965B publication Critical patent/MX391965B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se da a conocer un compuesto de porfirina y una composición elaborada a partir del mismo, la cual comprende una dosis terapéuticamente efectiva de una porfirina que se enlaza por medio de un enlazador a un agente contra el cáncer útil en el tratamiento de cáncer en un paciente que tenga una necesidad del mismo, o para el tratamiento de las células de cáncer in vitro. Los compuestos y las composiciones se pueden suministrar a través de un dispositivo de suministro fármaco como se da a conocer en la presente descripción y puede ser parte de un kit.
MX2018015916A 2016-06-16 2017-06-16 Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. MX391965B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351165P 2016-06-16 2016-06-16
PCT/US2017/037982 WO2017218959A1 (en) 2016-06-16 2017-06-16 Porphyrin compounds and compositions useful for treating cancer

Publications (2)

Publication Number Publication Date
MX2018015916A MX2018015916A (es) 2019-03-28
MX391965B true MX391965B (es) 2025-03-21

Family

ID=60664322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015916A MX391965B (es) 2016-06-16 2017-06-16 Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.

Country Status (8)

Country Link
US (2) US11590233B2 (es)
EP (1) EP3471774A4 (es)
JP (1) JP2019523783A (es)
CN (1) CN109922834B (es)
AU (1) AU2017283653C1 (es)
CA (1) CA3028122A1 (es)
MX (1) MX391965B (es)
WO (1) WO2017218959A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957921A1 (en) 2014-07-22 2016-01-28 Nmc, Inc. Improved carbon fixation systems in plants and algae
AU2017283653C1 (en) 2016-06-16 2022-05-05 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
JP7544372B2 (ja) * 2020-05-27 2024-09-03 学校法人福岡大学 ナトリウムチャネル結合剤及び医薬組成物
WO2022006436A2 (en) * 2020-07-01 2022-01-06 Bioaffinity Technologies, Inc. Compositions and methods for cellular delivery of rna
CN117417331A (zh) * 2023-10-16 2024-01-19 华中科技大学 一种基质调控类药物-半花菁的偶联物及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5587792U (es) 1978-12-05 1980-06-17
JPS5587792A (en) * 1978-12-27 1980-07-02 Green Cross Corp:The Meso-tetra(p-carboxyphenyl)porphine derivative
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4485086A (en) 1983-04-11 1984-11-27 Wong Dennis W Radiolabeled tumor imaging agent and method of preparation
US4889120A (en) 1984-11-13 1989-12-26 Gordon Robert T Method for the connection of biological structures
US4930516B1 (en) 1985-11-13 1998-08-04 Laser Diagnostic Instr Inc Method for detecting cancerous tissue using visible native luminescence
US4783529A (en) 1985-12-03 1988-11-08 Research Corporation Technologies Rapid synthesis of radiolabeled porphyrin complexes for medical application
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US4857300A (en) 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same
US5004811A (en) 1987-12-24 1991-04-02 Nippon Petrochemicals Company, Ltd. Tetrapyrrole aminocarboxylic acids
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
FR2656866B1 (fr) * 1990-01-10 1992-05-15 Cis Bio Int Derives de porphyrine et metalloporphyrines eventuellement couples a une molecule biologiquement active, et composition pharmaceutique les contenant.
US5238940A (en) 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
AU655942B2 (en) 1990-10-05 1995-01-19 Queen's University At Kingston Porphyrin derivatives
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
DE19503163A1 (de) 1995-02-01 1996-08-08 Bayer Ag Verfahren zur Reinigung von 4-Hydroxybenzaldehyd enthaltenden Reaktionsgemischen
US6706473B1 (en) 1996-12-06 2004-03-16 Nanogen, Inc. Systems and devices for photoelectrophoretic transport and hybridization of oligonucleotides
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
US20020155999A1 (en) 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
JP3753866B2 (ja) 1998-07-01 2006-03-08 株式会社日立製作所 自己救済型光ネットワーク
US6091843A (en) 1998-09-03 2000-07-18 Greenvision Systems Ltd. Method of calibration and real-time analysis of particulates
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
WO2000066528A2 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Quinones for treatment of diseases
US7904139B2 (en) 1999-08-26 2011-03-08 Non-Invasive Technology Inc. Optical examination of biological tissue using non-contact irradiation and detection
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6984498B2 (en) 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
ES2380261T3 (es) 2000-11-17 2012-05-10 Biomoda, Inc. Composiciones y métodos para la detección de afecciones precancerosas en muestras de células y tejidos utilizando 5, 10, 15, 20-tetrakis(carboxifenil)porfina.
US7344710B2 (en) 2001-11-21 2008-03-18 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
AU2003279756A1 (en) * 2002-06-26 2004-01-19 Cellgate, Inc. Porphyrin-polyamine conjugates for cancer therapy
WO2004002476A2 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
EP1386927B1 (en) 2002-08-02 2005-03-30 Institut Curie Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors
US20040192665A1 (en) * 2002-08-02 2004-09-30 Slil Biomedical Corporation Conjugates of porphyrin compounds with chemotherapeutic agents
EP1594875A4 (en) * 2003-01-16 2007-07-11 Technomart Co Ltd PORPHYRINE DERIVATIVES
US7400396B2 (en) 2003-02-13 2008-07-15 Hamanatsu Photonics K.K. Fluorescent correalated spectrometric analysis device
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7682603B2 (en) 2003-07-25 2010-03-23 The Trustees Of The University Of Pennsylvania Polymersomes incorporating highly emissive probes
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US8198246B1 (en) 2004-10-05 2012-06-12 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20070172392A1 (en) 2005-12-13 2007-07-26 Sen Chandan K Apparatus, system and method for tissue oximetry
US8180436B2 (en) 2006-04-12 2012-05-15 The Invention Science Fund I, Llc Systems for autofluorescent imaging and target ablation
US8168586B1 (en) 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
US8983581B2 (en) 2008-05-27 2015-03-17 Massachusetts Institute Of Technology System and method for large field of view, single cell analysis
US9155471B2 (en) 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
ES2651068T3 (es) 2009-07-17 2018-01-24 Bioaffinity Technologies, Inc. Sistema y procedimiento de análisis de muestras marcadas con 5,10,15,20 tetraquis(4 carboxifenil)porfirina (TCPP)
US9156849B2 (en) * 2011-08-12 2015-10-13 Biolitec Pharma Marketing Ltd Application of β-functionalized dihydroxy-chlorins for PDT
CN102617610B (zh) * 2012-03-31 2013-12-11 哈尔滨工业大学 卟啉类光敏剂与抗癌药二联体的制备方法
US20140011985A1 (en) * 2012-07-09 2014-01-09 Maria Zannes Targeted Cancer Therapy Conjugates Using Porphyrins and Porphyrin-like Molecules and Various Cytotoxic Agents
US9439976B2 (en) 2013-02-13 2016-09-13 The Methodist Hospital System Compositions and methods for using cathepsin E cleavable substrates
AU2017283653C1 (en) 2016-06-16 2022-05-05 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer

Also Published As

Publication number Publication date
EP3471774A1 (en) 2019-04-24
AU2017283653C1 (en) 2022-05-05
AU2017283653B9 (en) 2021-09-16
CN109922834B (zh) 2022-09-23
WO2017218959A1 (en) 2017-12-21
EP3471774A4 (en) 2020-04-15
CA3028122A1 (en) 2017-12-21
CN109922834A (zh) 2019-06-21
AU2017283653A1 (en) 2019-01-31
US20190184021A1 (en) 2019-06-20
JP2019523783A (ja) 2019-08-29
US11590233B2 (en) 2023-02-28
WO2017218959A4 (en) 2018-02-08
US20230302144A1 (en) 2023-09-28
AU2017283653B2 (en) 2021-09-09
MX2018015916A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
MX391965B (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
TW201613578A (en) Pharmaceutical combinations
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2019011749A (es) Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia.
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
RU2012158011A (ru) Метод и композиция для лечения рака
BR112018070580A2 (pt) métodos e composições para terapia com células t car